AMCP Format 4.1 includes new sections describing the evidence needs of HCDMs for unapproved products nearing the end of the product development pipeline, as well as unapproved uses of existing products for which FDA approval is being sought.
On Jan. 5, AMCP joined the Pharmacy Health Information Technology (PHIT) Collaborative and national pharmacy stakeholders in submitting comments to CMS on its Medicaid prior authorization proposed rule. AMCP supports expanding use of electronic prior authorizations, removing barriers to health information technology adoption and providing patients and providers with information regarding prior authorization decisions.
AMCP will occasionally publish highlights from AMCP and other conferences designed for those in managed care pharmacy. Highlights include summaries of select featured session and posters. Meetings published currently include the AAD Virtual Meeting, ASCO Virtual Scientific Program, Assembia 2020, AMCP eLearning Days, NAMCP, AAAAI Annual Meeting, 2019 ACR/ERP Annual Meeting and AMCP Nexus 2019.
On Dec. 21, CMS published a Final Rule to support state flexibility to enter into value-based purchasing arrangements (VBPs) with drug manufacturers, and to allow manufacturers with qualifying VBPs to report multiple best price points for a single dosage form and strength of a covered outpatient drug. The final rule is effective on Jan. 1, 2022.